Pfizer Inc. (PFE) is a leading company in the Drug Manufacturers—General industry, operating within the healthcare sector. As of the latest market close, Pfizer’s stock price stands at $26.72, reflecting a 1.18% decrease from the previous day.
Recent Stock Performance
Over the past year, Pfizer’s stock has shown varied performance:
- Year-to-Date Return: 3.02%
- 1-Year Return: 9.45%
- 3-Year Return: 38.01%
- 5-Year Return: 6.93%
These figures compare to the S&P 500’s returns of 25.70% (YTD), 36.94% (1-Year), 27.63% (3-Year), and 94.33% (5-Year), indicating that while Pfizer has had steady growth, it has underperformed relative to the broader market in some periods.
Market Dynamics and Analyst Insights
The stock’s 52-week range fluctuated between $25.20 and $31.54, showcasing moderate volatility. Pfizer’s current market capitalization is approximately $151.42 billion, with an average trading volume of 31.75 million shares.
Analyst recommendations are diverse, but the consensus indicates a moderate outlook for Pfizer. The average 1-year target estimate is $32.89, suggesting potential upside from the current price. Key analyst ratings include:
- Cantor Fitzgerald: Overweight
- BMO Capital: Outperform
- Truist Securities: Buy
Financial Highlights
| Metric | Value |
|---|---|
| Market Cap | $155.62 billion |
| Enterprise Value | $212.28 billion |
| Trailing P/E Ratio | 36.61 |
| Forward P/E Ratio | 9.22 |
| PEG Ratio (5-year expected) | 0.73 |
| Price/Sales (TTM) | 2.62 |
| Profit Margin | 7.16% |
| Return on Assets (TTM) | 3.31% |
| Return on Equity (TTM) | 4.54% |
| Total Revenue (TTM) | $59.38 billion |
| Gross Profit (TTM) | $40.72 billion |
Comparative Analysis with Industry Peers
For a comprehensive understanding, it’s beneficial to compare Pfizer with its industry counterparts:
| Company | Stock Price | % Change | Market Cap |
|---|---|---|---|
| Pfizer Inc. (PFE) | $26.72 | -1.18% | $151.42B |
| Merck & Co., Inc. (MRK) | $102.92 | +1.73% | $260.35B |
| Bristol-Myers Squibb Company (BMY) | $54.14 | -1.04% | $109.81B |
| Johnson & Johnson (JNJ) | $155.47 | -0.80% | $374.31B |
| Eli Lilly and Company (LLY) | $831.54 | +4.27% | $789.39B |
This comparison highlights Pfizer’s position in the market relative to major players in the pharmaceutical industry.
Recent News Impacting Pfizer
Several recent developments are noteworthy:
- Pfizer announced a plan to invest $1 billion in China over the next five years to enhance drug development efforts in the region.
- Discussions around vaccine stocks have been influenced by political factors, with potential impacts from figures like RFK Jr. being considered by investors.
- Analysts are evaluating Pfizer’s performance, especially in light of COVID-19 products driving third-quarter results. Some are questioning the sustainability of this growth.
Expert Outlook
From an expert perspective, Pfizer’s future growth may hinge on several factors:
- Pipeline Development: Ongoing research and development efforts are crucial for long-term success.
- Global Expansion: Investments in markets like China could open new revenue streams.
- Market Competition: Staying competitive against other pharmaceutical giants requires innovation and strategic positioning.
Investors should monitor Pfizer’s strategic initiatives and market conditions to make informed decisions.
Conclusion
Pfizer Inc. remains a significant player in the pharmaceutical industry. While facing challenges, the company’s strategic investments and market position provide a foundation for potential growth. As always, it’s important for investors to conduct thorough research and consider market trends when evaluating their investment choices.